Following up their recent fundraising announcement, Antiverse have secured a multi-year, multi-target partnership agreement with up front and milestones with Nxera (extra points for perfect pronunciation). GPCR-targeting drugs are the largest family of drug discovery targets – comprising 1/3 of all FDA approved drugs - they generated $160bn in revenue in 2022 alone. They're also one of the most difficult targets to develop for (we in the marketing team had this difficulty described to us as owing to the 'floppiness' of receptors; apparently not a technical term). Nxera is the 4th most successful company by cumulative license value in the world (since 2015) and specialises in GPCRs. This is one of the first major partnerships of this kind that we've been able to announce for a DSV portfolio company, we're very proud of the team!
We’ve entered a multi-target partnership and licensing agreement with Antiverse to design antibodies for GPCRs. The collaboration combines Antiverse’s generative AI antibody design expertise with our NxWave™ platform with the aim to bring transformative therapies for multiple diseases of high unmet need. Read the full announcement here: https://lnkd.in/eDFux8gD